Swiss National Bank Acquires 7,700 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Swiss National Bank increased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 0.8% during the 4th quarter, HoldingsChannel reports. The firm owned 972,292 shares of the company’s stock after purchasing an additional 7,700 shares during the period. Swiss National Bank’s holdings in Elanco Animal Health were worth $11,774,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Elanco Animal Health during the 3rd quarter valued at about $35,000. Jones Financial Companies Lllp lifted its stake in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after acquiring an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. lifted its stake in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after acquiring an additional 3,411 shares in the last quarter. Blue Trust Inc. lifted its stake in Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after acquiring an additional 1,894 shares in the last quarter. Finally, Spire Wealth Management lifted its stake in Elanco Animal Health by 107.4% in the 4th quarter. Spire Wealth Management now owns 7,776 shares of the company’s stock valued at $94,000 after acquiring an additional 4,026 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 2.2 %

NYSE:ELAN opened at $10.60 on Friday. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $5.24 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a twelve month low of $10.03 and a twelve month high of $18.80. The stock’s 50 day moving average price is $11.38 and its two-hundred day moving average price is $12.64.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s revenue was down 1.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.08 earnings per share. Equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were purchased at an average cost of $10.90 per share, with a total value of $109,000.00. Following the acquisition, the director now directly owns 101,459 shares in the company, valued at $1,105,903.10. This represents a 10.93 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.57% of the stock is owned by insiders.

Analysts Set New Price Targets

ELAN has been the topic of several research reports. Piper Sandler cut their target price on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Morgan Stanley cut their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus cut their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Finally, Leerink Partners assumed coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.